First gene therapy Glybera finally gets CHMP nod in Europe
This article was originally published in Scrip
Executive Summary
Glybera (alipogene tiparvovec) has finally received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), paving the way for it to become the first approved gene therapy in Europe. The product has been developed to treat the rare inherited disease lipoprotein lipase deficiency (LPLD) for which there is at present no approved treatment.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.